BIOSTAX CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.033 USD | -8.33% |
|
-8.33% | -54.79% |
| 05-20 | Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-16 | Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 6.11M 479M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -235M | Net income 2023 | -1M -78.41M | EV / Sales 2022 | - |
| Net Debt 2022 | 546K 42.81M | Net Debt 2023 | 1.15M 90.5M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-6
x | P/E ratio 2023 |
-3.65
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 31.15% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -8.33% | ||
| 1 week | -8.33% | ||
| Current month | -30.08% | ||
| 1 month | -30.08% | ||
| 3 months | -45.00% | ||
| 6 months | -53.52% | ||
| Current year | -54.79% |
1 week
0.03
0.04
1 month
0.030.04
Current year
0.030.08
1 year
0.030.90
3 years
0.037.99
5 years
0.0349.90
10 years
0.03640.00
| Managers | Title | Age | Since |
|---|---|---|---|
Noreen Griffin
FOU | Founder | 71 | 01/12/93 |
Glen Farmer
DFI | Director of Finance/CFO | 55 | 01/08/22 |
Robert Wilson
BRD | Director/Board Member | 51 | 30/05/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Wilson
BRD | Director/Board Member | 51 | 30/05/22 |
Mary Caperton
BRD | Director/Board Member | 62 | 23/10/23 |
Roger Suro
BRD | Director/Board Member | 50 | 11-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/05/24 | 0.033 | -8.33% | 8,518 |
Delayed Quote OTC Markets, May 28, 2024 at 06:33 pm
More quotes
Biostax Corp. is a developer and marketer of pharmaceutical, biotechnology, and MedTech products. The Company has partnerships in the fields of autoimmunity and immune restoration and are able to deliver solutions today for people that are living with autoimmunity, chronic inflammation, infection, and cancer. Its internal and partner programs comprised of JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models; Lodonal, is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), and LDN, which is a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.
| 1st Jan change | Capi. | |
|---|---|---|
| -54.79% | 3.01M | |
| +9.83% | 118B | |
| +10.80% | 106B | |
| -10.84% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.11% | 15.97B | |
| +6.62% | 14.03B | |
| +17.53% | 11.67B |
- Stock Market
- Equities
- BTAX Stock
